Abstract
Background: The human microbiome is a dynamic and diverse community of microorganisms that affects susceptibility to illness and promotes wellness. Dysbiosis, or disruption of this delicately regulated microbial ecology, has been identified as a major factor in the emergence and development of systemic and organ‐specific disorders. Objective: With an emphasis on dysbiosis‐driven illness processes and therapeutic intervention implications, this study attempts to critically analyze host–microbiome interactions across key human organ systems. Methods: Using predetermined microbiome‐related keywords, a systematic literature search (2001–2025) was carried out in PubMed, Scopus, Web of Science, and Google Scholar. To assess microbiome formation, organ‐specific distribution, disease correlations, and therapeutic implications, English‐language peer‐reviewed original papers, meta‐analyses, and clinical or validated animal studies were chosen and methodically compiled. Results: Microbiome dysbiosis is linked to cardiovascular, metabolic, inflammatory, neurological, hepatic, renal, and cancer‐related illnesses by interfering with immune modulation, metabolic balance, and epithelial barrier integrity, according to evidence from human and verified animal research. Modified production of short‐chain fatty acids, immunological signaling imbalance, chronic inflammation, and communication between the gut–organ axis are examples of mechanistic linkages. Immune and metabolic indicators improved condition‐specifically with interventions such as probiotics, fecal microbiota transplantation, and diet‐based regulation. Conclusion: Collectively, current evidence supports the microbiome as a modifiable determinant of disease risk and therapeutic response, underscoring its translational potential for precision medicine.

This publication has 218 references indexed in Scilit: